S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
2 stocks that faded their price gaps after crushing earnings
Give up the OPEC fight with these 3 stocks, Buffett-certified
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
10-year yield is below 4.5%...these dividend growth yields aren’t
AI revolution: 3 stocks set to soar as technology evolves
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Is there money hiding under these 2 mattress stocks?
3 reasons a squeeze could be in Paramount's coming attractions

Agenus (AGEN) Competitors

$0.66
-0.03 (-4.35%)
(As of 11/27/2023 ET)
Compare
Today's Range
$0.65
$0.69
50-Day Range
$0.63
$1.24
52-Week Range
$0.61
$3.07
Volume
11.60 million shs
Average Volume
5.20 million shs
Market Capitalization
$251.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.10

AGEN vs. NVAX, BCRX, ALVO, VYGR, AURA, HUMA, SOPH, FATE, CHRS, and FENC

Should you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Alvotech (ALVO), Voyager Therapeutics (VYGR), Aura Biosciences (AURA), Humacyte (HUMA), SOPHiA GENETICS (SOPH), Fate Therapeutics (FATE), Coherus BioSciences (CHRS), and Fennec Pharmaceuticals (FENC). These companies are all part of the "biological products, except diagnostic" industry.

Agenus vs.

Novavax (NASDAQ:NVAX) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, community ranking, valuation, earnings, dividends and media sentiment.

Novavax has a net margin of -52.29% compared to Novavax's net margin of -280.44%.

Company Net Margins Return on Equity Return on Assets
Novavax-52.29% N/A -30.74%
Agenus -280.44%N/A -73.24%

In the previous week, Novavax and Novavax both had 2 articles in the media. Agenus' average media sentiment score of 0.21 beat Novavax's score of -0.58 indicating that Novavax is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novavax
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Agenus
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Negative

Novavax has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500. Comparatively, Agenus has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500.

Agenus has lower revenue, but higher earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$1.98B0.33-$657.94M-$6.37-0.86
Agenus$98.02M2.57-$220.07M-$0.82-0.81

Novavax currently has a consensus price target of $25.00, indicating a potential upside of 357.88%. Agenus has a consensus price target of $8.10, indicating a potential upside of 1,126.72%. Given Novavax's stronger consensus rating and higher possible upside, analysts clearly believe Agenus is more favorable than Novavax.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novavax
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
Agenus
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Novavax received 379 more outperform votes than Agenus when rated by MarketBeat users. Likewise, 74.34% of users gave Novavax an outperform vote while only 70.38% of users gave Agenus an outperform vote.

CompanyUnderperformOutperform
NovavaxOutperform Votes
840
74.34%
Underperform Votes
290
25.66%
AgenusOutperform Votes
461
70.38%
Underperform Votes
194
29.62%

71.5% of Novavax shares are owned by institutional investors. Comparatively, 55.4% of Agenus shares are owned by institutional investors. 0.9% of Novavax shares are owned by company insiders. Comparatively, 4.8% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Novavax and Agenus tied by winning 8 of the 16 factors compared between the two stocks.


Get Agenus News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGEN vs. The Competition

MetricAgenusBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$251.90M$2.55B$4.40B$6.69B
Dividend YieldN/A2.38%2.98%20.29%
P/E Ratio-0.818.76138.9313.58
Price / Sales2.57181.992,661.31154.58
Price / CashN/A23.4221.4722.84
Price / Book-3.673.203.804.49
Net Income-$220.07M$55.51M$121.43M$176.13M
7 Day Performance-3.04%1.59%2.84%2.08%
1 Month Performance-15.63%12.55%13.22%9.44%
1 Year Performance-75.36%4.16%5.01%2.53%

Agenus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NVAX
Novavax
2.0195 of 5 stars
$5.35
-6.1%
$25.00
+367.3%
-67.0%$677.10M$973.73M-0.841,992
BCRX
BioCryst Pharmaceuticals
2.1994 of 5 stars
$5.10
-5.6%
$13.22
+159.3%
-56.7%$1.04B$317.56M-4.08531
ALVO
Alvotech
0 of 5 stars
$9.01
-1.4%
$9.33
+3.6%
+62.8%$281.56M$63.17M0.00917Upcoming Earnings
Gap Down
VYGR
Voyager Therapeutics
2.3297 of 5 stars
$6.71
-1.9%
$17.00
+153.4%
+25.6%$295.21M$158.40M5.46125
AURA
Aura Biosciences
1.963 of 5 stars
$7.99
-3.9%
$21.00
+162.8%
-42.1%$305.70MN/A-4.1270
HUMA
Humacyte
1.9057 of 5 stars
$2.44
-5.1%
$7.75
+217.6%
-19.2%$252.72M$1.57M-2.80164
SOPH
SOPHiA GENETICS
1.8578 of 5 stars
$3.86
+4.0%
$6.33
+64.1%
+83.2%$244.49M$58.71M-3.61466News Coverage
Gap Up
FATE
Fate Therapeutics
2.2004 of 5 stars
$2.45
-5.8%
$10.44
+326.0%
-88.5%$241.58M$106.21M-1.38551Gap Down
CHRS
Coherus BioSciences
2.5413 of 5 stars
$1.99
-3.9%
$12.78
+542.1%
-70.5%$230.52M$211.07M-0.76299
FENC
Fennec Pharmaceuticals
1.8448 of 5 stars
$8.63
+1.1%
$16.50
+91.2%
-11.6%$229.86M$13.05M-11.21N/ANegative News

Related Companies and Tools

This page (NASDAQ:AGEN) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -